U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis - Bristol-Myers Squibb

* U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis  Bristol-Myers Squibb * BMS's deucravacitinib approved for plaque psoriasis  FiercePharma * FDA approves new drug for plaque psoriasis treatment  Medical News Today * New Drug OK'd for Treatment of Plaque Psoriasis  Healthline * Deucravacitinib Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis  Rheumatology Network * View Full Coverage on Google News
http://dlvr.it/SY6qLz